Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Immermann, Frederick"'
Autor:
Creech, C. Buddy, Frenck, Robert W., Jr, Sheldon, Eric A., Seiden, David J., Kankam, Martin K., Zito, Edward T., Girgenti, Douglas, Severs, Joseph M., Immermann, Frederick W., McNeil, Lisa K., Cooper, David, Jansen, Kathrin U., Gruber, William, Eiden, Joseph, Anderson, Annaliesa S., Baber, James
Publikováno v:
In Vaccine 5 January 2017 35(2):385-394
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1980 Sep 01. 77(9), 5385-5389.
Externí odkaz:
https://www.jstor.org/stable/9336
Autor:
Douglas Girgenti, Kathrin U. Jansen, David A. Cooper, Edward T. Zito, William C. Gruber, Eric Sheldon, Immermann Frederick, C. Buddy Creech, Robert W. Frenck, Joseph Eiden, Joseph M. Severs, James Baber, Lisa K. McNeil, Annaliesa S. Anderson, Martin K. Kankam, David J. Seiden
Publikováno v:
Vaccine. 35:385-394
Background The decline in immune function with age is a challenge to vaccine development. Following an initial study in adults aged 18–64 years, this study evaluated the safety and immunogenicity of Staphylococcus aureus (S. aureus) 4-antigen (SA4A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73036fa3cd9a0501c57d8e6489894bb8
https://doi.org/10.1016/j.vaccine.2016.11.032
https://doi.org/10.1016/j.vaccine.2016.11.032
Autor:
Bechard Theresa, Ryan Mark, LaVallie Edward R, Young Deborah, Corcoran Christopher, Immermann Frederick W, Ramsey Renee C, Hill Andrew A, Guo Yongjing, Pfeifer Richard, Warner Garvin, Bologna Marcia, Bloom Laird, O'Toole Margot
Publikováno v:
Journal of Translational Medicine, Vol 8, Iss 1, p 50 (2010)
Abstract Background Selective neutralization of the IL21/IL21R signaling pathway is a promising approach for the treatment of a variety of autoimmune diseases. Ab-01 is a human neutralizing anti-IL21R antibody. In order to ensure that the activities
Externí odkaz:
https://doaj.org/article/d81a46fb9576409bb1516323716aa216
Publikováno v:
Crustaceana, 1979 Mar 01. 36(2), 166-172.
Externí odkaz:
https://www.jstor.org/stable/20103378
Autor:
Immermann Frederick, Mark Ryan, Edward R. Lavallie, Laird Bloom, Margot O'Toole, Renee Ramsey, Christopher John Corcoran, Garvin Warner, Deborah Young, Yongjing Guo, Theresa Bechard, Marcia Bologna, Andrew A. Hill, Richard Pfeifer
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 8, Iss 1, p 50 (2010)
Journal of Translational Medicine, Vol 8, Iss 1, p 50 (2010)
Background Selective neutralization of the IL21/IL21R signaling pathway is a promising approach for the treatment of a variety of autoimmune diseases. Ab-01 is a human neutralizing anti-IL21R antibody. In order to ensure that the activities of Ab-01
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9575cf6313ec580cc28d01ee05522c74
https://doi.org/10.1186/1479-5876-8-50
https://doi.org/10.1186/1479-5876-8-50
Autor:
Aikaterini Thanou, P. W. Wu, T. Zhou, Padmalatha S. Reddy, Stan Kamp, Immermann Frederick, Margot O'Toole, Sudhakar Sridharan, W. Mounts, Joan T. Merrill, Andrew A. Hill, Judith A. James, Maryann Z. Whitley, Theresa Paradis, Joel M. Guthridge, Ying Zhang, D. von Schack, J.L. Masferrer
Publikováno v:
Annals of the Rheumatic Diseases. 73:525.3-526
Background The BOLD study investigated biologic effects of commonly used immune suppressants (IS) on SLE patients (pts), evaluating the safety of withdrawing IS from stable pts in trials. We have reported (1) that this protocol was well tolerated and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fa69070879c44666a2937962a387f8d
https://doi.org/10.1136/annrheumdis-2014-eular.2788
https://doi.org/10.1136/annrheumdis-2014-eular.2788
Autor:
Immermann Frederick, T. Zhou, Sudhakar Sridharan, Joan T. Merrill, Aikaterini Thanou, Judith A. James
Publikováno v:
Annals of the Rheumatic Diseases. 72:A482.1-A482
Background The choice of composite clinical assessment tools in lupus clinical trials is expanding, but it is important to understand the differences between what these endpoints measure. The SLE Responder Index (SRI) was developed for the successful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f320061d3975c89be635988de51377b
https://doi.org/10.1136/annrheumdis-2013-eular.1445
https://doi.org/10.1136/annrheumdis-2013-eular.1445
Autor:
Maryann Z. Whitley, Padmalatha S. Reddy, Joan T. Merrill, W. Mounts, Attila A. Seyhan, T. Walker, T. Zhou, Immermann Frederick, Margot O'Toole, Sudhakar Sridharan, Ying Zhang, Andrew A. Hill, Judith A. James, Stan Kamp, Marek Honczarenko, J. Masferrer
Publikováno v:
Annals of the Rheumatic Diseases. 71:74.2-74
Background Heterogeneity of clinical manifestations and underlying biology has confounded treatment development and optimal care of systemic lupus erythematosus (SLE) patients. About half of adult SLE patients tend to have stable, high expression lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a87837fed6c2119cb690cc48730cdc98
https://doi.org/10.1136/annrheumdis-2012-eular.1746
https://doi.org/10.1136/annrheumdis-2012-eular.1746
Autor:
Sudhakar Sridharan, P. W. Wu, Margot O'Toole, Andrew A. Hill, Immermann Frederick, Maryann Z. Whitley, T. Paradis, Joan T. Merrill, Judith A. James, J. Masferrer, Padmalatha S. Reddy, T. Zhou, Ying Zhang
Publikováno v:
Annals of the Rheumatic Diseases. 72:A369.3-A370
Background Elevated expression of IFN pathway genes, known as the IFN signature (IS) is found in roughly half of SLE patients 1 . Various studies have used different IFN genes to define the IS, and different methods to assign patients to “IFN high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5e9b6a45ea46c5e46925946b5048f80
https://doi.org/10.1136/annrheumdis-2013-eular.1131
https://doi.org/10.1136/annrheumdis-2013-eular.1131